Condition: Hormone Receptor-positive Breast Cancer · Hormone Receptor Positive HER-2 Negative Breast Cancer · Metastatic Breast Cancer · Sponsor: Ellipses Pharma
The aim of this study is to identify the optimal dose for EP0062 as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
This description comes directly from the study's public registry record.
Clinical Trials Team · +44 (0)20 3743 0992 · Enquiries@ellipses.life
Always discuss trial participation with your own doctor first.
| Yale School of Medicine | New Haven, Connecticut, United States | Completed |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Henry Ford Hospital | Detroit, Michigan, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| Texas Oncology Baylor University Medical Center | Dallas, Texas, United States | Recruiting |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
| Hospital 12 de Octubre | Usera, Madrid, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron (VHIO) | Barcelona, Spain | Recruiting |
| Hospital Universitario Ramón y Cajal | Madrid, Spain | Recruiting |
| NEXT Oncology Hospital Quironsalud | Madrid, Spain | Recruiting |
| Sarah Cannon Research Institute UK | London, London, United Kingdom | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05573126